# Junta clínica — PT-pseudo_926c37508fe2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_926c37508fe2",
  "pid": "PT-pseudo_926c37508fe2",
  "task": 1,
  "psa": 5.4,
  "age": 67,
  "months": 2,
  "pirads": "2",
  "psad": 0.143,
  "psav": 0.96,
  "psap": 4.2,
  "vol": 37.82,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7259888,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "simvastatin, rosuvastatin, paracetamol PRN, tamsulosin",
  "notes": "PSA 5.4 ng/mL. PI-RADS 2. PSAD 0.14. Prostate volume 38 mL. csPCa 0.73.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [
    "Iodinated contrast (mild)"
  ],
  "vitals": {
    "weight": "78 kg",
    "height": "175 cm",
    "bmi": "25.5",
    "bp": "115/59 mmHg",
    "hr": "60 bpm",
    "smoking": "Current smoker (39 pack-yr)",
    "last_dental": "1 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "27 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Seeking specialist reassessment due to escalating PSA levels and a prior biopsy bucket Positive."
    },
    {
      "s": "History",
      "t": "A 67-year-old retired civil servant with a established urological background, first brought to clinical attention by an incidental PSA rise in 2023. He currently smokes and carries a 39 pack-year history. Moderate lower urinary tract symptoms are present, currently controlled with tamsulosin and paracetamol PRN, yielding an IPSS score of 12. His urological record documents a prior biopsy in 2023 that confirmed ISUP GG 2 adenocarcinoma. Systemic health includes hypercholesterolaemia, chronic kidney disease, and osteoarthritis, managed with simvastatin and rosuvastatin. He maintains an alcohol-free lifestyle, dedicates his time to gardening, and lives alone despite being married. Recent clinical engagements feature endocrinology-led thyroid screening, six physiotherapy sessions addressing stable lower back discomfort, and an orthopaedic review for knee osteoarthritis. He voices considerable apprehension about invasive procedures and has asked for detailed explanations regarding any potential interventions."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate presents as symmetrically enlarged with a smooth, homogeneous consistency, lacking palpable nodules or asymmetry. Vital signs remain stable, recording a blood pressure of 115/59 mmHg and a regular heart rate of 60 bpm. General examination is unremarkable, with clear lung fields and a soft, non-tender abdomen."
    }
  ],
  "occupation": "retired civil servant",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Physiotherapy — lower back, six sessions",
    "Orthopaedic outpatient — knee follow-up"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Gardening, no structured exercise",
  "ipss": "IPSS score: 12/35 (moderate LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_926c37508fe2
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 5.4 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.143 ng/mL²
  - PSA velocity: 0.96 ng/mL/yr
  - Prior PSA: 4.2 ng/mL
  - Prostate volume: 37.82 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7259888 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: simvastatin, rosuvastatin, paracetamol PRN, tamsulosin
  - Allergies: Iodinated contrast (mild)
  - Additional notes: PSA 5.4 ng/mL. PI-RADS 2. PSAD 0.14. Prostate volume 38 mL. csPCa 0.73.

Vitals: weight 78 kg, height 175 cm, BMI 25.5, BP 115/59 mmHg, HR 60 bpm. Smoking: Current smoker (39 pack-yr).

Chief complaint: Seeking specialist reassessment due to escalating PSA levels and a prior biopsy bucket Positive.

History: A 67-year-old retired civil servant with a established urological background, first brought to clinical attention by an incidental PSA rise in 2023. He currently smokes and carries a 39 pack-year history. Moderate lower urinary tract symptoms are present, currently controlled with tamsulosin and paracetamol PRN, yielding an IPSS score of 12. His urological record documents a prior biopsy in 2023 that confirmed ISUP GG 2 adenocarcinoma. Systemic health includes hypercholesterolaemia, chronic kidney disease, and osteoarthritis, managed with simvastatin and rosuvastatin. He maintains an alcohol-free lifestyle, dedicates his time to gardening, and lives alone despite being married. Recent clinical engagements feature endocrinology-led thyroid screening, six physiotherapy sessions addressing stable lower back discomfort, and an orthopaedic review for knee osteoarthritis. He voices considerable apprehension about invasive procedures and has asked for detailed explanations regarding any potential interventions.

Physical examination: DRE: The prostate presents as symmetrically enlarged with a smooth, homogeneous consistency, lacking palpable nodules or asymmetry. Vital signs remain stable, recording a blood pressure of 115/59 mmHg and a regular heart rate of 60 bpm. General examination is unremarkable, with clear lung fields and a soft, non-tender abdomen.

Patient info: retired civil servant; Married; Lives alone.
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Gardening, no structured exercise; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Physiotherapy — lower back, six sessions; Orthopaedic outpatient — knee follow-up.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.14 epistemic (95% band 0.19-0.75); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PI-RADS 1-2 on the current mpMRI: there is no lesion to sample. In the labelled series this criterion matched the reading urologist in 2 of 2 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.42: PI-RADS 2, PSA 4.7, PSAD 0.14, age 67, DRE Normal -> DEFER (clear). He wrote: "Priads 2 with only sightly elevated PSA"
  2. distance 1.69: PI-RADS 2, PSA 8.3, PSAD 0.206, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with low-risk cancer on active surveillance. Now normal MRI."
  3. distance 2.05: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a stable MRI (PI-RADS 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15. The guideline recommends offering active surveillance (AS) as standard of care to all suitable patients with low-risk disease and selected patients with favourable intermediate-risk disease.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of no biopsy is not decisively supported by the guideline because the guideline does not account for the patient's prior positive biopsy status in its primary decision-making framework. EXPERT-COHORT, your criterion focusing only on PI-RADS 1-2 does not address the guideline's consideration of prior biopsy status as a decisive factor.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: at Positive, the guideline implies that this status is a key factor in determining the next step, which is what the conference must establish.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline mentions a stable PSA-D < 0.15ng/ml/cc as a factor that might lead to avoiding biopsy.
laboratory_results - the PSA density: the guideline specifies a threshold of < 0.15ng/ml/cc for low-risk disease consideration.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the details of the prior biopsy result and the specific values from the PSA trend and laboratory results to determine if the EAU criteria for low-risk disease exclusion are met.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the mpMRI report indicate whether the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA velocity?
  previous_notes (get_previous_notes) -> What was the grade (Gleason/ISUP) of the prior biopsy, and is a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What is the PSA density?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What was the Gleason/ISUP grade of the prior biopsy?
  Q2. What is the PSA velocity and PSA density from the laboratory results?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "No PI-RADS 3+ lesion identified."

psa_trend
What is the PSA velocity?: PSA velocity is 0.96 ng/mL/yr.

previous_notes
What was the grade (Gleason/ISUP) of the prior biopsy, and is a surveillance protocol in place?: The grade of the prior biopsy was ISUP GG 2 adenocarcinoma, and a surveillance protocol is not explicitly mentioned.

laboratory_results
What is the PSA density?: The PSA density is 0.143 ng/mL/mL.

WHAT I DID NOT OPEN
I did not open the family-history anamnesis because the existing notes and other data provide sufficient context for the current decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now
Prior biopsy: Positive (from previous_notes)
PSA density: 0.143 ng/mL/mL (meets the EAU threshold for low-risk consideration)

AGAINST sampling this patient now
mpMRI finding: PI-RADS 2 (from radiology_report)
EAU guideline: Suggests active surveillance is standard for low-risk disease.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 5.40 ng/mL over 4 points spanning 20 months; velocity +1.89 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 7.4 ng/mL, conformal 95% band 2.1-25.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.12 epistemic (95% band 0.09-0.56), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.33  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 2 of 2 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have answered the moderator's questions. The `previous_notes` provided the prior biopsy grade (ISUP GG 2 adenocarcinoma), the `psa_trend` provided the PSA velocity (0.96 ng/mL/yr), and the `laboratory_results` provided the PSA density (0.143 ng/mL/mL).

ALIGNMENT WITH THE PANEL
The retrieved findings align with the PANEL-PROTOCOL's answer of NO BIOPSY, as the PSA density (0.143 ng/mL/mL) meets the EAU threshold for low-risk consideration, and the PI-RADS 2 finding was the rule that fired in the protocol.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What was the Gleason/ISUP grade of the prior biopsy? Answered by the Registrar: ISUP GG 2 adenocarcinoma.
Q2. What is the PSA velocity and PSA density from the laboratory results? Answered by the Registrar: PSA velocity is 0.96 ng/mL/yr, and PSA density is 0.143 ng/mL/mL.

WHAT CARRIES WEIGHT, AND WHY
The PSA density (0.143 ng/mL/mL) is highly relevant as it directly relates to the EAU guideline threshold for low-risk disease consideration. The prior positive biopsy status is also a key factor weighted by the trace model.

MY SUGGESTION TO THE CHAIR
I suggest deferral, as the retrieved data supports the panel's conclusion that the low PSA density and PI-RADS 2 finding, in the context of the prior positive biopsy, align with the guideline recommendation for active surveillance.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

67y male, PSA 5.4, PSAD 0.143, PI-RADS 2, prior positive biopsy, no prior grade recorded. Stable MRI finding with low PSAD argues against repeat biopsy. Follow PSA trend and re-image if rise occurs.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
